Highlights on cabozantinib with nivo and ipi for intermediate_poor risk adv. RCC_COSMIC-313

• Date : 14/09/2022
• 21    
  1

Highlights on ADT duration with post-operative radiotherapy in prostate cancer_RADICALS-HD

• Date : 14/09/2022
• 16    
  0

Highlights on first-line atezolizumab in NSCLC not eligible for platinum_ The IPSOS study

• Date : 14/09/2022
• 15    
  0

Highlights on Sotorasib in NSCLC with KRAS G12C mutation_ The CodeBreaK 200 study

• Date : 14/09/2022
• 9    
  0

Highlights on neoadj. vs adjuvant pembrolizumab in resected stage III-IV melanoma_SWOG S1801

• Date : 14/09/2022
• 8    
  0

Highlights on the efficacy and safety of fruquintinib in refractory mCRC_ The FRESCO-2 study

• Date : 14/09/2022
• 8    
  0

Highlights on pembrolizumab with CRT in locally advanced HNSCC_ The KEYNOTE-412 study

• Date : 14/09/2022
• 6    
  0

Congrès ESMO 2026

• Date : 23/10/2026
• 51    
  0

Congrès ESMO d'Immuno-Oncologie 2025

• Date : 10/12/2025
• 137    
  0

SABCS 2025 Symposium

• Date : 09/12/2025
• 5332    
  0

Congrès ESMO Asie 2025

• Date : 05/12/2025
• 306    
  0

17ᵉ Congrès Européen Multidisciplinaire sur le Cancer Urologique - EMUC25

• Date : 13/11/2025
• 464    
  0